Independent. No paid rankings. Our evidence grades are never for sale. Where a cosmetic or skincare product passes our review, we may link to it with a disclosed affiliate link. Reviewed weekly Editorial policy Newsletter

Home›Explore peptides›Kisspeptin

Kisspeptin

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 1 October 2026Funding No vendor payment

Genuinely one of the better human-trial-backed compounds we cover — real human studies on ovulation triggering and a controlled trial on brain activity tied to sexual desire. Almost none of that trial evidence has anything to do with how it's marketed to consumers.

Evidence grade B: what kinds of studies support the claims on this page, with limits. It is not a verdict on any product. How we grade

On this page

  1. What it is
  2. What the trial evidence shows
  3. The gap between the trials and the consumer product

In brief

Should you care? This is a case where real, peer-reviewed human trial evidence exists — more of it than for almost anything else we cover — but it comes from specialist reproductive-endocrinology research, not from anything resembling a consumer libido product.

The short version

  • Real, published human studies from a credible academic research group (Imperial College London): a dose-ranging IVF study with no comparison group, and a randomized trial of kisspeptin against vehicle.
  • Two distinct applications studied: triggering egg maturation in IVF, and brain activity linked to sexual/emotional processing.
  • Not an approved product — given in monitored research settings, not as a consumer supplement.

Correction, 1 October 2026

This page previously described both kisspeptin studies as “controlled” and the 2017 study as “double-blind, placebo-controlled” with intravenous dosing. PubMed’s records show the 2014 IVF study (PMID 25036713) as a clinical trial in which all 53 women received kisspeptin-54 at one of four doses, with no comparison group described, and the 2017 study (PMID 28112678) as a randomized controlled trial (indexed as double-blind) comparing kisspeptin with vehicle in 29 healthy men. The abstracts do not state the route of administration, so the page no longer does. The same wording was also removed from the key points (“IV/subcutaneous infusion”), the section on consumer products (“controlled infusion protocols”) and the sentence calling the 2017 study “the first controlled human demonstration”; only that 2017 paper is described as randomized and vehicle-controlled. The Library card and tracker row were corrected to match. No evidence grade changed.

Further correction, 1 October 2026: the sentence above saying the abstracts do not state the route was wrong for the 2014 study, whose abstract states a single subcutaneous injection (as the study description below already says). The 2017 abstract does not state a route. The route field in the summary no longer lists “IV/subcutaneous”, and no route is given for the 2017 study. The phrase “as an alternative to conventional triggers”, which the 2014 abstract does not state, was also removed from the study description.

What it is

Kisspeptin is the peptide product of the KISS1 gene — the body's own master regulator of the reproductive hormone axis (GnRH/LH secretion). Kisspeptin-54 is the major circulating human form, and the one used in the trials below.

What the trial evidence shows

Jayasena et al. (J Clin Invest 2014;124(8):3667-3677, PMID 25036713) gave a single subcutaneous injection of kisspeptin-54, at one of four doses, to 53 women undergoing IVF, with no comparison group described in the abstract; egg maturation was observed at every dose tested. Comninos et al. (J Clin Invest 2017;127(2):709-719, PMID 28112678) compared kisspeptin with vehicle in 29 healthy men in a randomized trial and found it enhanced limbic-system brain activity during sexual and romantic-bonding imagery, with measured improvements on behavioral and mood scales — in the authors’ words, evidence of “an undescribed role for kisspeptin in integrating sexual and emotional brain processing with reproduction in humans.” Both are real, peer-reviewed studies from the same Imperial College London reproductive endocrinology research group; only the second compared kisspeptin with a control (vehicle).

The gap between the trials and the consumer product

Consumer "kisspeptin" products — nasal sprays, injectable vials sold for libido or hormone balance — bear no real relationship to the research protocols, exact doses, or monitored clinical settings the trials above actually used. It is not an approved drug for any use, and remains investigational, administered only under research protocols. This is a case where unusually solid trial evidence exists, but doesn't remotely resemble how the compound reaches consumers — worth holding both facts at once rather than letting one stand in for the other.

What you can do next

References

  1. Jayasena et al., "Kisspeptin-54 Triggers Egg Maturation in Women Undergoing In Vitro Fertilization," J Clin Invest 2014;124(8):3667-3677, PMID 25036713.
  2. Comninos et al., "Kisspeptin Modulates Sexual and Emotional Brain Processing in Humans," J Clin Invest 2017;127(2):709-719, PMID 28112678.